Stock News

Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Biogen Announces Two New Nominees for Election to Board of Directors
Is It Too Late to Buy Biogen (BIIB) Stock?
Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
Is This Another Strike Against Biogen's Alzheimer's Drug?
How Biogen Makes Money?
Is Biogen (BIIB) Stock A Buy or Sell?
3 Reasons to Buy Sage Therapeutics, and 1 Reason to Pass
Before You Buy Biogen, Stop and Consider These 3 Things

As seen on...